Kyowa Kirin, Inc.

Clinical trials sponsored by Kyowa Kirin, Inc., explained in plain language.

Now part of Kyowa Kirin Co., Ltd. 4151 TOKYO

A pharmaceutical company developing medicines.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Trials to join now! 1

New drug KK2223 enters early human testing for Tough-to-Treat T-Cell lymphoma

Disease control Recruiting now

This early-stage trial is testing an experimental drug called KK2223 in 72 adults with T-cell lymphoma (a type of blood cancer) that has returned or not responded to prior treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processe…

Phase 1 • Sponsor: Kyowa Kirin, Inc. • Aim: Disease control

Last updated Aug 23, 2026 00:00 UTC

Kyowa Kirin, Inc.

New drug KK2223 enters early human testing for Tough-to-Treat T-Cell lymphoma